Biotage Launches New EVOLUTE CX

1 post / 0 new
Shizank's picture
Biotage Launches New EVOLUTE CX

Biotage Launches New EVOLUTE CX for Improved
Sample Preparation

(February 25, 2008) Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, announced the introduction of the new EVOLUTE CX sample preparation range. EVOLUTE CX is a mixed-mode resin-based SPE sorbent for the extraction of basic drugs from biological fluids using a generic procedure, minimizing method development time for bioanalysts. EVOLUTE CX removes protein, phospholipids, and salt interferences, delivering cleaner extracts with high reproducibility for accurate quantitation and trouble-free analyses through pre-clinical and clinical trials.

Biotages EVOLUTE CX uses a combination of robust polymer chemistry, uniform coverage of sulfonic acid (SO3-) groups and optimum exchange capacity to provide greater than 85% recovery on a broad range of sample matrices. The surface characteristics of every batch are tested to ensure consistency. A combination of optimized pore size, sorbent chemistry and associated generic method results in extremely clean extracts for LCMS/MS.

The Biotage EVOLUTE family of products now includes EVOLUTE ABN (30m and 50m) and EVOLUTE CX. EVOLUTE products provide highly effective solutions to the problems of ion suppression and matrix effects from dirty extracts. These high performance products allow scientists to use a generic approach for a wide range of compounds, reducing method development time while improving extract cleanliness.

Biotage offers a wide range of sample preparation tools for Bioanalytical, Clinical, Environmental, Food and Forensic applications. With a variety of sorbent chemistries and formats, IST sorbents deliver cleaner extracts with higher analyte recovery for precise analysis.

For more information on Biotages EVOLUTE CX sample preparation products, please visit booth #2934 at PITTCON 2008, from 1-7 March 2008. Alternatively please email eval(unescape('%64%6f%63%75%6d%65%6e%74%2e%77%72%69%74%65%28%27%3c%61%20%68%72%65%66%3d%22%6d%61%69%6c%74%6f%3a%70%72%6f%64%75%63%74%5f%69%6e%66%6f%40%62%69%6f%74%61%67%65%2e%63%6f%6d%22%3e%70%72%6f%64%75%63%74%5f%69%6e%66%6f%40%62%69%6f%74%61%67%65%2e%63%6f%6d%3c%2f%61%3e%27%29%3b')) or visit

For further press information please contact: Eleanor CallanMonk, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel: +44 1477 539539 Fax: +44 1477 539540 e-mail: eval(unescape('%64%6f%63%75%6d%65%6e%74%2e%77%72%69%74%65%28%27%3c%61%20%68%72%65%66%3d%22%6d%61%69%6c%74%6f%3a%62%69%6f%74%61%67%65%40%73%63%6f%74%74%70%72%2e%63%6f%6d%22%3e%62%69%6f%74%61%67%65%40%73%63%6f%74%74%70%72%2e%63%6f%6d%3c%2f%61%3e%27%29%3b'))

About Biotage
Biotage is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the areas of genetic analysis and medicinal chemistry. Customers include the worlds top 30 pharmaceutical companies, 20 largest biotech companies and leading academic institutes. The company is headquartered in Uppsala and has offices in the US, Japan, UK and several other European countries. Biotage has approx. 330 employees and had pro-forma sales of approx. 500 MSEK in 2004. Biotage is listed on the Stockholm stock exchange. Website:

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," and "should," among others. These forward-looking statements are based on Biotages current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Biotage notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the microwave synthesis and flash purification in the drug discovery market, DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Biotages products (including seasonal fluctuations), difficulties in successfully adapting the Companys products to integrated solutions and producing such products, and the Companys ability to identify and develop new products and to differentiate its products from competitors.

Jennifer Whedbee
Director Marketing Communications
Tel: +1 434 220 2652